Central to Big Pharma’s lobbying efforts is relying on drug company-funded “nonprofit” groups to sanitize their goals under the veneer of charity. Investigative reporting in Tarbell, a media organization founded by healthcare activist Wendell Potter, shows that drug companies, namely Eli Lilly, successfully lobbied the Obama administration to make Internet companies embrace policies that curtail online access to affordable medication.
These pharma-funded nonprofits engage fellow industry-tied patient groups, the media and people, promoting the idea that rogue online pharmacies and safe international online pharmacies are the same thing. Their message: don’t buy lower-cost medications online from other countries because it’s too dangerous.
That message is an outright lie.
Tagged with: Alliance for Safe Online Pharmacies, ASOP, Big Pharma, Eli Lilly, LegitScript, Obama Administration, tarbell
There are not many issues you can hear both Republicans and Democrats clapping about in unison, but high drug prices is definitely one of them. Echoing his 2016 campaign, President Trump again proclaimed during his State of the Union address Tuesday night that his administration is determined “to make fixing the injustice of high drug prices one of our top priorities.”
Speeding up the approval of lower-cost generics was noted by Trump as “exciting progress,” but nothing substantial has been done by the Trump administration on drug prices. The appointment of Alex Azar to head the Department of Health and Human Services department was a major disappointment. As president of Eli Lilly USA, Azar oversaw major price hikes on lifeline medications, such as insulin.
Appealing to both his base and popular opinion, President Trump could use his executive authority immediately to more expressly permit Americans to buy medication from international pharmacies.
Tagged with: Alex Azar, Eli Lilly, executive authority, State of The Union, trump
Last month, I published an op-ed in The Guardian in opposition to Alex Azar for Secretary of Health and Human Services. In advance of the Senate Finance Committee Hearing tomorrow over his nomination, I’m publishing my article in its entirety below.
Recently, the president announced Alex Azar as his nominee to lead the US Department of Health and Human Services, saying: “He will be a star for better healthcare and lower drug prices!” People like me – experts in drug policy and advocates for lowering drug costs for American patients – know that nothing could be farther from the truth.
On average, Americans pay twice as much for life-saving drugs as consumers in other developed countries. It doesn’t have to be this way, but unfortunately, Azar might think so.
On Wednesday, Azar appeared before the Senate Health, Education, Labor and Pensions committee. While he stated his commitment to lowering drug prices, he declined to support the two solutions that would have the greatest impact on patients. In fact, he and his company have vigorously opposed policies that would make healthcare more affordable for the rest of us. (more…)
Tagged with: Alex Azar, Eli Lilly, HHS